Windlas Biotech Ltd

Windlas Biotech Ltd experienced a significant intraday decline on 11 Feb 2026, touching a low of Rs 782, down 8.11% from its previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and subdued market sentiment within the Pharmaceuticals & Biotechnology space.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance, as reflected in recent indicator signals. Despite a modest day gain of 1.82%, the company’s technical parameters present a complex picture with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, prompting a downgrade in its Mojo Grade from Hold to Sell on 4 February 2026.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent upgrade in price, the stock remains under pressure from mixed monthly technicals and a downgraded Mojo Grade, signalling caution for investors navigating the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently experienced a shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly indicators, monthly signals suggest caution, reflecting a complex interplay of market forces that investors should carefully consider.

Windlas Biotech Ltd., a small-cap contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported mixed results for Q3 FY26, with net profit declining 15.73% quarter-on-quarter to ₹15.00 crores despite achieving the highest quarterly revenue in company history. The ₹1,660 crore market capitalisation company continues to demonstrate strong top-line momentum with 19.53% year-on-year revenue growth, but profitability challenges have emerged as a significant concern for investors.

Windlas Biotech Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable shift in its technical outlook and financial performance. The company’s improved technical indicators, steady financial trends, and fair valuation underpin this revised stance, despite some lingering concerns over long-term growth and recent underperformance relative to the broader market.

Windlas Biotech Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, signalling a potential consolidation phase. Recent technical indicators present a mixed picture, with weekly charts showing mild bullishness while monthly signals remain cautiously bearish. This nuanced technical landscape warrants close attention from investors seeking to gauge the stock’s near-term trajectory within the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 November 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Windlas Biotech Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from a Hold to a Sell rating by MarketsMOJO, the stock’s price action and key technical indicators suggest a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing caution for investors amid a challenging market backdrop.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Windlas Biotech Ltd recorded a robust intraday performance on 14 Jan 2026, surging 7.03% to touch a day’s high of Rs 867, significantly outperforming the Pharmaceuticals & Biotechnology sector and broader market indices.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 11 January 2026, providing investors with an up-to-date view of the company's performance and outlook.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by a combination of financial trends, valuation considerations, and technical indicators. This development comes amid a challenging year for the small-cap pharmaceutical and biotechnology company, which has seen its stock performance diverge notably from broader market indices.

Windlas Biotech has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters amid a backdrop of subdued stock performance and sector challenges. This adjustment highlights evolving perspectives on the company’s financial health, valuation, and technical outlook within the Pharmaceuticals & Biotechnology sector.